Last reviewed 2026-04-19 · How we verify

HFA-152A propellant

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma (PHASE3)
• A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive (PHASE1)
• Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). (PHASE3)
• A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive (PHASE1)
• A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma (PHASE1)
• Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants (PHASE1)
• Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance (PHASE1)
• A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HFA-152A propellant CI brief — competitive landscape report
• HFA-152A propellant updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI